GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Pancreatic Polypeptide

Company
University Hospital, Gentofte, Copenhagen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for Pancreatic Polypeptide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07506369

    Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans

    Not yet reported University Hospital, Gentofte, Copenhagen 18 participants Est. completion 2028-10 1 site
    Other conditions: Obesity & Overweight
    View official trial listing →
  • Terminated NCT NCT00002947

    Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

    Not yet reported Yale University 35 participants Est. completion 2004-08 1 site
    Other conditions: Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Intraocular Melanoma, Islet Cell Tumor, Kidney Cancer, Lung Cancer, Melanoma (Skin), Neoplastic Syndrome, Neuroendocrine Carcinoma of the Skin, Pheochromocytoma
    View official trial listing →
  • Completed NCT NCT00005842

    Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

    Not yet reported National Cancer Institute (NCI) 24 participants 2 sites
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT00005860

    Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum

    Not yet reported Memorial Sloan Kettering Cancer Center 1 site
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT00006368

    Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

    Not yet reported Novartis Pharmaceuticals 60 participants Est. completion 2003-11 1 site
    Other conditions: Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00027638

    Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2003-12 1 site
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00096083

    Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

    Not yet reported Delcath Systems Inc. 56 participants Est. completion 2012-08 1 site
    Other conditions: Cancer
    View official trial listing →
  • Terminated NCT NCT00227617

    Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

    Not yet reported, Not yet reported University of California, San Francisco 36 participants Est. completion 2016-02 2 sites
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
    View official trial listing →
  • Withdrawn NCT NCT00227773

    Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

    Not yet reported Eastern Cooperative Oncology Group
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00416767

    Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery

    Not yet reported Federation Francophone de Cancerologie Digestive 20 participants Est. completion 2007-07
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00427349

    AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

    Not yet reported Eastern Cooperative Oncology Group 46 participants Est. completion 2015-04 112 sites
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
    View official trial listing →
  • Status unknown NCT NCT00454376

    Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

    National Cancer Institute (NCI) 408 participants 16 sites
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Metastatic Cancer, Neoplastic Syndrome
    View official trial listing →
  • Terminated NCT NCT00466856

    Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

    Not yet reported Vanderbilt-Ingram Cancer Center 10 participants Est. completion 2007-10 1 site
    Other conditions: Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
    View official trial listing →
  • Completed NCT NCT00538850

    Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

    Not yet reported INSYS Therapeutics Inc 130 participants Est. completion 2010-10 1 site
    Other conditions: Cancer
    View official trial listing →
  • Completed NCT NCT00602082

    Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors

    Not yet reported Cambridge University Hospitals NHS Foundation Trust 84 participants Est. completion 2009-12 17 sites
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
    View official trial listing →
  • Completed NCT NCT00652405

    Effect of Alcohol on Cephalic Phase Reflex and Gene Expression

    Not yet reported TNO 24 participants Est. completion 2008-07 1 site
    Type 2 diabetes Other conditions: Inflammation, Carbohydrate&Lipid Metabolism, Oral Processing
    View official trial listing →
  • Terminated NCT NCT00730483

    Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors

    Not yet reported Yale University 13 participants Est. completion 2014-06 1 site
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
    View official trial listing →
  • Terminated NCT NCT00791076

    The Effect of Pancreatic Polypeptide on Insulin Requirements for Type 1 & Post-pancreatectomy Diabetic Patients

    Not yet reported Johns Hopkins University 8 participants Est. completion 2010-06 1 site
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT01052493

    A First-Time-in-Human Study to Assess the Safety and Tolerability of PP 1420 in Healthy Subjects

    Not yet reported Imperial College London 13 participants Est. completion 2010-10-18 1 site
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT01951729

    The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion

    Not yet reported Washington University School of Medicine 15 participants Est. completion 2015-05 1 site
    Prediabetes
    View official trial listing →
  • Terminated NCT NCT02221765

    Safety, Tolerability and Efficacy Study of PP1420 in HV

    Not yet reported, Not yet reported Imperial College London 49 participants Est. completion 2016-05 1 site
    Other conditions: Obesity
    View official trial listing →
  • Enrolling by invitation NCT NCT03338387

    Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia

    Not yet reported Charles University, Czech Republic 24 participants Est. completion 2026-12-20
    Obstructive sleep apnea Other conditions: Eating Disorder
    View official trial listing →
  • Completed NCT NCT03396146

    Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes

    Not yet reported Assistance Publique - Hôpitaux de Paris 36 participants Est. completion 2019-12-18 1 site
    Other conditions: Type1diabetes
    View official trial listing →
  • Completed NCT NCT03854708

    Effect of Pancreatic Polypeptide on Gastric Motor Function and Food Intake in Humans

    Not yet reported Universitaire Ziekenhuizen KU Leuven 12 participants Est. completion 2011-03-08 1 site Stand-alone
    Other conditions: Hunger
    View official trial listing →
  • Status unknown NCT NCT04514588

    Associations Between Genetic Markers of Caffeine Metabolism, Appetite Hormones and Body Weight

    Not yet reported Gkouskou Kalliopi 70 participants Est. completion 2022-06-30 1 site
    Other conditions: Food Consumption and Appetite, Food Habits, Caffeine
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Pancreatic Polypeptide, Pancreatic Polypeptide (PP)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.